de
Performance
Financial Reports
Press Releases
Share Buyback Programme
Factsheets
Securities
Management Transactions
Disclosure of Shareholdings
Company Presentation
Calendar
FAQ
News Registration
Contact
Sitemap
Company
Profile
Strategy
Investment Guidelines
Organisation
Board of Directors
Management
Cayman Subsidiary
Investment Manager
Investment Advisor Europe
Investment Advisor USA
Corporate Governance
Articles of Association
Portfolio
Monthly Overview
Quarterly Overview
Largest Investments
Private Companies
Specialised Venture Capital Funds
Public Companies
Investors
Performance
Share Price
Net Asset Value (NAV)
Financial Reports
Press Releases
Share Buyback Programme
Factsheets
Securities
Management Transactions
Disclosure of Shareholdings
Company Presentation
Calendar
FAQ
News Registration
Contact
Downloads
Financial Reports
Financial Reports 2010/2011
Financial Reports 2009/2010
Archive
Press Releases
2010
2009
Archive
Capital Market Transactions
Company Presentation
Corporate Documents
Contact
HBM BioVentures Ltd
Cayman Subsidiary
Investment Manager
Investment Advisor Europe
Investment Advisor USA
Contact Form
News
Press Releases
»
HBM BioVentures Quarterly Report as at 30 June 2010
»
HBM BioVentures’ largest public investment – Micrus – acquired
by Johnson & Johnson
»
HBM BioVentures sells USD hedging position at a profit
»
Shareholders’ meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM BioVentures shares and intensify cooperation
»
Archive
Financial Reports
»
Quarterly Report June 2010
»
Annual Report 2009/2010
»
Archive
Share Price
SIX Swiss Exchange Ticker
HBMN
Key Figures
as at 31.8.2010
CHF
NAV
per share
62.58
Net assets
616 Mio.
Search
News Registration
Sign up now
